603669 Lionco Pharmaceutical Group
- 6.08
- +0.04+0.66%
Lionco Pharmaceutical Group News
Lingkang Pharmaceutical: Announcement on subsidiary cefuroxime sodium for injection passing the generic drug consistency evaluation
Announcement on the subsidiary\'s injectable cefuroxime passing the generic drug consistency evaluation
Lingkang Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form for November 3, 2024
Lingkang Pharmaceutical: Third Quarter Report 2024
Third Quarter Report 2024
Convertible debt-to-equity conversion results and share change announcement
Announcement on the cancellation of the pledge of some of the shares of the controlling shareholder
Announcement on the deferral of the controlling shareholder\'s pledged share repurchase transaction
Announcement on the subsidiary levocarnitine injection passing the generic drug consistency evaluation
Announcement on the subsidiary\'s injectable cefazoxime sodium passing the generic drug consistency evaluation
Notice on the change of sponsor representative to continue to supervise
Half-year report for the year 2024.
Announcement of the Resolution of the 19th Meeting of the Fourth Board of Directors.
Special report on the annual deposit and use of funds for the first half of 2024
Announcement of Resolution of the Fifteenth Meeting of the Fourth Supervisor Board.
Summary of Half-Year Report in 2024.
Announcement regarding the subsidiary's cephalosporin injection sodium sulbactam passing the generic consistency evaluation.
Announcement concerning the lifting of the pledge of shares by the controlling shareholder.
Announcement on Not Lowering the Conversion Price of Lingkang Convertible Bonds
Announcement regarding the expectation of meeting the share conversion price adjustment conditions for "Lingkang Convertible Bonds".
Analysis
Price Target
No Data
No Data